Nanoform narrows Q2 loss as revenue rises 16% year over year

Nanoform Finland reported a narrower second-quarter loss as revenue rose 16% year over year, according to the company's earnings release. The company's revenue for the period reached EUR 800,000, a 16% increase from the same period last year, with a gross margin of 84% and gross profit of EUR 700,000. Nanoform's adjusted earnings per share loss also narrowed during the quarter, with an EBITDA loss of EUR 3 million, down from the prior year due to a 36% drop in operating costs.

The reductions were a result of layoffs and part-time layoffs implemented earlier in the year. Additionally, Nanoform signed an exclusivity agreement with a U.S. biopharma partner for biologics nanoparticle technology during the quarter. The positive feedback from the UK MHRA supports a potentially faster and less expensive approval route for nanoenzalutamide, for which Nanoform expects to submit its first market authorization application before the end of 2026.

The company aims to increase the number of non-GMP and GMP projects signed compared to 2025 and maintain cash burn below EUR 10 million for 2026.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.